Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.
Having now secured regulatory approval for all three of its haemophilia A therapies made in Berkeley, Bayer is implementing “organisational changes” across the facility.
Novartis’ experimental marketing strategy, whereby the pharma giant used its scale to insure against failed CAR-T therapies, helped defend Kymriah from competition, says consultant.
Provisional results from a survey evaluating the reputations of major biopharmaceutical countries indicate the US, Germany and Japan are regarded as ‘tier one’ nations, followed closely by Sweden and the UK.
Eli Lilly’s migraine treatment was approved by the US FDA, closely following a positive CHMP opinion, and will potentially be made available without cost for the first year.
The California Department of Insurance has sued AbbVie for allegedly providing monetary gifts to health-care providers for prescribing its biologic, Humira.
As the stream of executives flowing from large pharma companies to smaller biotechs builds into a torrent, another month has passed with a number of significant switches. Notably, two former Genentech employees, responsible for work on some of its bestselling...
